Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
Researchers want to learn if combining lasofoxifene and abemaciclib works well in people with advanced breast cancer. This treatment will be compared to the usual breast cancer treatment with fulvestrant and abemaciclib. The people in this study have breast cancer that is fueled by estrogen and does not have the HER2 protein. They also have a mutation (change or variant) in the ESR1 gene. Lasofoxifene targets the ESR1 gene mutation.
Mycosis fungoides (MF) is a disease in which lymphocytes (a type of white blood cell) become cancerous and affect the skin, causing "cutaneous T-cell lymphoma." Lymphomatoid papulosis (LyP) is a rare and similar disorder that causes lymphoma-like skin lesions.
The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).
Researchers are doing this study to learn if lung chemoembolization is safe and works well in people with lung cancer. The people in this study have non-small cell lung cancer that keeps growing after chemotherapy. Moreover, it cannot be cured with surgery or radiation therapy.
Researchers are assessing treatment with BGB-16673 in combination with other anti-cancer medications in people with B-cell cancers. These cancers include:
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (131I) in the laboratory to form the radioactive compound 131I-MIBG. The 131I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
